The UK Medicines and Healthcare Products Regulatory Agency (UK-MHRA) recently inspected the solid dosages manufacturing facility of Indoco Remedies Limited in Goa (Plant I) from September 7 to September 9, 2026.

As per the company, UK-MHRA current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations.

Aditi Panandikar, Managing Director – Indoco Remedies Ltd. said, “This plant has been consistently catering to the regulated markets of UK, Europe, South Africa, New Zealand, Australia and Canada for several years and is expected to contribute to approx. 30% of total international business.”

“The successful completion of the UKMHRA cGMP inspection with no critical or major observations is a strong validation of our robust quality systems. This further testifies our unwavering commitment to Good Manufacturing Practices and world class quality standards,” added Panandikar.

The facility which manufactures solid dosages and liquid dosages is approved by USFDA, (solid dosages, creams and capsules), TGA-Australia (solid dosages, liquid orals, creams and ointments) and by EU Malta, i.e., MMA - Malta Medicine Authority (solid dosages).

The plant also holds WHO-GMP approval and has successfully faced audit by SAHPRA (for solid dosages).